Researchers assessing ocrelizumab have reported positive results in the treatment of primary growing MS, a rticularly aggressive form of the disease.
The disease affects almost three sses as many women as men and can cause a range of symptoms including vision problems, equilibrium, dizziness, memory loss, tremors, loss of speech and sexual mind-bogglers.
MS symptoms typically appear when people are in their 20s and 30s and can include monstrosity loss, disability and fatigue. It’s an unpredictable condition – one day a person with MS mightiness be fine but the next they might lose their sight or be powerless to move.
The results, published in The New England Journal of Medicine, showed that 33 per cent of tients charming the drug deteriorated over time com red with 39 per cent of those alluring a placebo.
tients taking the drug also displayed less wisdom loss in scans, and scored better on the time needed to walk 25ft (7.6m).
Dr Peter Calabresi, from Johns Hopkins University in Baltimore, mean: “This is the first drug to show a significant effect in slowing handicap progression in a phase three trial in primary progressive multiple sclerosis, and for that reason the trial represents a landmark study in the field.”
More than 100,000 woman in the UK have MS.
The research involved testing on more than 700 resolutes by scientists at institutions across the US and Europe.
It was sponsored by ocrelizumab’s manufacturer, Roche.
The medicament has been accepted for review for use by the European Medicines Agency and the US Food and Analgesic Administration.
Two further trials also showed the drug’s ability to manage relapsing multiple sclerosis, characterised by distinct attacks which fall and go.
Dr Aisling McMahon is Head of Clinical Trials at the MS Society, said: “This is remarkably big news for people with the primary progressive form of multiple sclerosis.
“It’s the outset time any treatment has shown the potential to reduce disability progression for this kind of MS, which offers a lot of hope for the future.
“MS can be challenging and unpredictable and the 15,000 human being in the UK living with primary progressive MS currently have no treatments ready to slow the worsening of their condition.
“Before this treatment is nearby on the NHS it needs to be licensed by the European Medicines Agency and assessed for cost-effectiveness.”